Zobrazeno 1 - 10
of 93
pro vyhledávání: '"Jose Alejandro Perez-Fidalgo"'
Autor:
Debra Richardson, Jose Alejandro Perez Fidalgo, Antonio Gonzalez-Martin, Ana Oaknin, Erika Hamilton, John Hays, Bhavana Pothuri, Kyriakos Papadopoulos, Sara Taylor, Marilyn Huang, Yeh-Chen Lee, Thomas Krivak, Victor Moreno-Garcia, Emiliano Calvo, Leslie Randall, David Starks, Malcom Ross, Linda Duska, Bo Gao, Robert Poka, Emily Putiri, Jamie Barrett, Leslie Demars, Nicole Concin
Publikováno v:
E-Posters (Trials In Progress).
Autor:
Luis Augusto Teixeira, Rossella Graffeo, Luca Livraghi, Maria Vittoria Dieci, Estela Carrasco, Ann H. Partridge, Christine Rousset-Jablonski, Fabio Puglisi, Arlindo R. Ferreira, Albert Grinshpun, Matteo Lambertini, Jose Alejandro Perez-Fidalgo, Judith Balmaña, Cynthia Villarreal-Garza, Alberta Ferrari, Hatem A. Azim, Angela Toss, Shani Paluch-Shimon, Claire Senechal, Laura De Marchis, Katarzyna Pogoda, Riccardo Ponzone, Florian Clatot, Octavi Cordoba, Antonio Di Meglio, Olivier Caron, Kevin Punie, Claire Saule, Amir Sonnenblick, Philip D. Poorvu, Lucia Del Mastro, Maria Del Pilar Estevez-Diz, Marcello Ceppi, Lieveke Ameye, Anne-Sophie Hamy, Fedro A. Peccatori, Marco Bruzzone, François Duhoux
Publikováno v:
Cancer Research. 81:PD10-06
Background: Young breast cancer patients (pts) carrying a germline BRCA mutation (mBRCA) have similar outcomes as non-carriers. However, there is currently lack of evidence regarding the impact of mBRCA type and hormone receptor status on clinical be
Autor:
Alberta Ferrari, Lucia Del Mastro, Albert Grinshpun, Amir Sonnenblick, Sileny Han, Matteo Lambertini, Philip D. Poorvu, Jose Alejandro Perez-Fidalgo, Fedro A. Peccatori, Rossella Graffeo, Riccardo Ponzone, Hatem A. Azim, Shani Paluch-Shimon, Luca Livraghi, Luis Augusto Teixeira, Olivier Caron, Maria Vittoria Dieci, Anne-Sophie Hamy, Michail Ignatiadis, Estela Carrasco, Laura De Marchis, Gianmaria Miolo, Claire Senechal, Martine Berlière, Christine Rousset-Jablonski, Katarzyna Pogoda, Octavi Cordoba, Cynthia Villarreal-Garza, Anna Zingarello, Helena Luna Pais, Laura Cortesi, Claire Saule, Lieveke Ameye, Florian Clatot, Maria Del Pilar Estevez-Diz, Marianne Paesmans, Ann H. Partridge
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
PURPOSE Young women with germline BRCA mutations have unique reproductive challenges. Pregnancy after breast cancer does not increase the risk of recurrence; however, very limited data are available in patients with BRCA mutations. This study investi
Autor:
Debra Richardson, Christian Marth, Susana Banerjee, John Hays, Rebecca Arend, Jill Tseng, David Cibula, Jose Alejandro Perez Fidalgo, Antonella Savarese, Radoslaw Madry, Bhavana Pothuri, Robert Coleman, Bradley Monk, Mansoor Mirza, Isabelle Ray-Coquard, Patricia Bernardo, Emily Putiri, Azniv Shahverdyan, Robert Burger, Nicole Concin
Publikováno v:
Gynecologic Oncology. 166:S284
Autor:
Yoana Ivanova-Markova, Andrés Redondo, Carlota Moya-Alarcón, Almudena González-Domínguez, Vicente Gimeno-Ballester, Jose Alejandro Perez-Fidalgo, Maria-Pilar Barretina-Ginesta
Publikováno v:
Gynecologic oncology. 164(2)
Objective To estimate the cost-effectiveness of olaparib after being funded by the Spanish National Health Service (SNHS) as first-line monotherapy maintenance treatment in patients with advanced high-grade serous ovarian carcinoma (HGSOC) and BRCA m
Autor:
Andrés Redondo, M. Iglesias, E.M. Guerra, Ana Santaballa, L. Manso Sánchez, E. Calvo García, Ángel Fernández Cortés, Jose Alejandro Perez-Fidalgo, Y. García, Ana Oaknin, Antonio González-Martín, Mauricio Rubio, U. Bohn Sarmiento
Publikováno v:
ESMO Open
Esmo Open
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
Esmo Open
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Scientia
Background There is limited evidence for the benefit of olaparib in platinum-resistant ovarian cancer (PROC) patients with BRCA wild-type tumors. This study investigated whether this combination of a DNA-damaging chemotherapy plus olaparib is effecti
Autor:
R-M Espadero, Joop P. W. van den Bergh, Jose Alejandro Perez-Fidalgo, A. Gonçalves, Serafin Morales, Peter Schmid, D Adamson, KS Lee, Aleix Prat, Patrick Neven, Noelia Martínez, G. Jerusalem, Y-S Lu, S-A Im, J. Cortés, J.P. Crown, L Schlieker, Thomas Bogenrieder, D Chin-Lun Huang, M.P. Sablin
Publikováno v:
Cancer Research. 79:P6-21
Background: Xentuzumab (Xen), an IGF-1/-2-neutralizing Ab, binds IGF-1 and IGF-2, inhibits their growth-promoting signaling, and suppresses AKT activation by everolimus (Ev). This Phase 1b/2 trial evaluates Xen in combination with Ev and exemestane (
Autor:
Jose Alejandro Perez-Fidalgo, Ana Cristina Cercos Lleti, Luis Manso, Antonio Casado Herraez, Pedro Ventayol Bosch, Carla Garí, Miriam Padres Martí, Sergio Cedillo Gomez
Publikováno v:
Journal of Clinical Oncology. 40:e17591-e17591
e17591 Background: Olaparib, a poly (ADP-ribose) polymerase inhibitor (PARPi), monotherapy as first-line maintenance treatment has shown to be cost-effective in ovarian cancer (OC) patients with BRCA mutations in Spain. Regardless of BRCA status, pat
Autor:
Vicky Makker, Jose Alejandro Perez-Fidalgo, Alice Bergamini, Daniel Lewis Spitz, Toon Van Gorp, Jalid Sehouli, Jaroslav Klat, Tamar Perri, Amit M. Oza, Estrid Vilma Solyom Hogdall, Jason A. Konner, Eva M. Guerra, Francesco Raspagliesi, Stephanie Henry, Bradley J. Monk, Jeronimo Martinez Garcia, Brian M. Slomovitz, Sharon Shacham, Mansoor Raza Mirza, Ignace Vergote
Publikováno v:
Journal of Clinical Oncology. 40:5511-5511
5511 Background: Endometrial cancers (ECs) are stratified into four molecular categories: wild type TP53 with non-specific molecular profile typically with microsatellite stability (NSMP, p53wt/MSS), DNA polymerase ε exonuclease domain-mutated (POLE
Autor:
Alberta Ferrari, Lucia Del Mastro, Fabio Puglisi, Kevin Punie, Luis Augusto Teixeira, Albert Grinshpun, Riccardo Ponzone, François Duhoux, Jose Alejandro Perez-Fidalgo, Matteo Lambertini, Marcello Ceppi, Arlindo R. Ferreira, Maria Del Pilar Estevez-Diz, Estela Carrasco, Philip D. Poorvu, Christine Rousset-Jablonski, Marie Daphne t’Kint de Roodenbeke, Fedro A. Peccatori, Antonio Di Meglio, Judith Balmaña, Marco Bruzzone, Maria Vittoria Dieci, Anne-Sophie Hamy, Laura De Marchis, Cynthia Villarreal-Garza, Katarzyna Pogoda, Claire Saule, Octavi Cordoba, Rossella Graffeo, Luca Livraghi, Ann H. Partridge, Hatem A. Azim, Lieveke Ameye, Shani Paluch-Shimon, Claire Senechal, Florian Clatot, Olivier Caron, Amir Sonnenblick, Angela Toss
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-9 (2021)
Scientia
NPJ Breast Cancer
NPJ breast cancer, Vol. 7, no.1, p. 16 (2021)
Scientia
NPJ Breast Cancer
NPJ breast cancer, Vol. 7, no.1, p. 16 (2021)
Càncer de mama; Genètica del càncer Cáncer de mama; Genética del cáncer Breast cancer; Cancer genetics Young breast cancer (BC) patients carrying a germline BRCA pathogenic variant (mBRCA) have similar outcomes as non-carriers. However, the imp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5a0f6e34af3a7283e992c67a390f34e
https://lirias.kuleuven.be/handle/123456789/673414
https://lirias.kuleuven.be/handle/123456789/673414